ICR | Troubling data leads a biotech to pull its prized drug from market and FDA review

Troubling data leads a biotech to pull its prized drug from market and FDA review

The New York-based biotechnology company TG Therapeutics has decided to pull its only approved medicine from the market, after recent clinical trial data showed a potentially increased risk of death in cancer patients who received the drug in combination with one of TG's experimental therapies.

The oldest independent membership-led professional body for clinical researchers across the globe.